# A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

> **NCT07484724** · PHASE2 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 280 (estimated)

## Conditions studied

- Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** JS212
- **DRUG:** JS001
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT07484724
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-04-01
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07484724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07484724, "A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07484724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*